Diabetes mellitus is one of the most prevalent diseases and is associated with increased incidence of structural and functional derangements in the kidneys, eventually leading to end-stage renal disease in a significant fraction of afflicted individuals. The renoprotective effects of renin-angiotensin system (RAS) blockade have been established; however, the mechanistic pathways have not been fully elucidated. In this review article, the cardinal role of an activated RAS in the pathogenesis of diabetic nephropathy (DN) is discussed with a focus on 4 themes: (1) introduction to RAS cascade, (2) intrarenal RAS in diabetes, (3) clinical outcomes of RAS blockade in DN, and (4) potential of urinary angiotensinogen as an early biomarker of intrarenal RAS status in DN. This review article provides a mechanistic rational supporting the hypothesis that an activated intrarenal RAS contributes to the pathogenesis of DN and that urinary angiotensinogen levels provide an index of intrarenal RAS activity.
JossN, PatersonKR, DeighanCJ, . Diabetic nephropathy: how effective is treatment in clinical practice?QJM. 2002; 95: 41–49.
2.
MokdadAH, FordES, BowmanBA, . Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289: 76–79.
3.
BaysHE, BazataDD, ClarkNG, . Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the us population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). BMC Public Health. 2007; 7: 277.
4.
National Diabetes Information Clearinghouse. A Service of the National Institute of Diabetes and Digestive and Kidney Diseases. The National Institutes of Health, 2007.
5.
FordES, GilesWH, DietzWH.Prevalence of the metabolic syndrome among us adults: findings from the third national health and nutrition examination survey. JAMA. 2002; 287: 356–359.
6.
MitchellKD, NavarLG.Intrarenal actions of angiotensin II in the pathogenesis of experimental hypertension. In:LaraghJH, BrennerBM, eds.Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press; 1995: 1437–1450.
7.
KoboriH, NangakuM, NavarLG, . The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007; 59: 251–287.
8.
CareyRM, SiragyHM.The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab. 2003; 14: 274–281.
9.
SantosRA, Simoes e SilvaAC, MaricC, . Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor MAS. Proc Natl Acad Sci U S A. 2003; 100: 8258–8263.
10.
NavarLG, Prieto-CarrasqueroMC, KoboriH.Chapter 1: molecular aspects of the renal renin-angiotensin system. In:ReRN, DiPetteDJ, SchiffrinEL, ., eds.Molecular Mechanisms in Hypertension. Oxfordshire, UK: Taylor & Francis Medical; 2006: 3–14.
11.
DzauVJ, ReR.Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation. 1994; 89: 493–498.
12.
BaltatuO, SilvaJAJr, GantenD, . The brain renin-angiotensin system modulates angiotensin II-induced hypertension and cardiac hypertrophy. Hypertension. 2000; 35: 409–412.
13.
Dell'ItaliaLJ, MengQC, BalcellsE, . Compartmentalization of angiotensin II generation in the dog heart evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest. 1997; 100: 253–258.
14.
MazzocchiG, MalendowiczLK, MarkowskaA, . Role of adrenal renin-angiotensin system in the control of aldosterone secretion in sodium-restricted rats. Am J Physiol Endocrinol Metab. 2000; 278: E1027–E1030.
15.
DanserAH, AdmiraalPJ, DerkxFH, . Angiotensin I-to-II conversion in the human renal vascular bed. J Hypertens. 1998; 16: 2051–2056.
16.
GriendlingKK, MinieriCA, OllerenshawJD, . Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994; 74: 1141–1148.
17.
NavarLG, Harrison-BernardLM, NishiyamaA, . Regulation of intrarenal angiotensin II in hypertension. Hypertension. 2002; 39: 316–322.
18.
IngelfingerJR, ZuoWM, FonEA, . In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest. 1990; 85: 417–423.
19.
KamiyamaM, GarnerMK, FarragutKM, . The establishment of a primary culture system of proximal tubule segments using specific markers from normal mouse kidneys. Int J Mol Sci. 2012; 13: 5098–5111.
20.
KamiyamaM, FarragutKM, GarnerMK, . Divergent localizations of angiotensinogen mRNA and protein in proximal tubular segments of normal rat kidney. J Hypertens. 2012; 30: 2365–2372.
21.
TeradaY, TomitaK, NonoguchiH, . Pcr localization of angiotensin II receptor and angiotensinogen mRNAs in rat kidney. Kidney Int. 1993; 43: 1251–1259.
22.
RichouxJP, CordonnierJL, BouhnikJ, . Immunocytochemical localization of angiotensinogen in rat liver and kidney. Cell Tissue Res. 1983; 233: 439–451.
23.
DarbyIA, CongiuM, FernleyRT, . Cellular and ultrastructural location of angiotensinogen in rat and sheep kidney. Kidney Int. 1994; 46: 1557–1560.
24.
DarbyIA, SerniaC.In situ hybridization and immunohistochemistry of renal angiotensinogen in neonatal and adult rat kidneys. Cell Tissue Res. 1995; 281: 197–206.
25.
KoboriH, Harrison-BernardLM, NavarLG.Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol. 2001; 12: 431–439.
26.
PohlM, KaminskiH, CastropH, . Intrarenal renin angiotensin system revisited: role of megalin-dependent endocytosis along the proximal nephron. J Biol Chem. 2010; 285: 41935–41946.
27.
LeyssacPP.Changes in single nephron renin release are mediated by tubular fluid flow rate. Kidney Int. 1986; 30: 332–339.
28.
YanagawaN, CapparelliAW, JoOD, . Production of angiotensinogen and renin-like activity by rabbit proximal tubular cells in culture. Kidney Int. 1991; 39: 938–941.
SibonyM, GascJM, SoubrierF, . Gene expression and tissue localization of the two isoforms of angiotensin I converting enzyme. Hypertension. 1993; 21: 827–835.
32.
SchulzWW, HaglerHK, BujaLM, . Ultrastructural localization of angiotensin I-converting enzyme (EC 3.4.15.1) and neutral metalloendopeptidase (EC 3.4.24.11) in the proximal tubule of the human kidney. Lab Invest. 1988; 59: 789–797.
33.
VioCP, JeanneretVA.Local induction of angiotensin-converting enzyme in the kidney as a mechanism of progressive renal diseases. Kidney Int Suppl. 2003; 64: S57–S63.
34.
CasariniDE, BoimMA, StellaRC, . Angiotensin I-converting enzyme activity in tubular fluid along the rat nephron. Am J Physiol. 1997; 272: F405–F409.
35.
YeM, WysockiJ, WilliamJ, . Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006; 17: 3067–3075.
36.
SolerMJ, YeM, WysockiJ, . Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009; 296: F398–F405.
37.
ParkS, BivonaBJ, KoboriH, . Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J physiol Renal Physiol. 2010; 298: F37–F48.
38.
AndersonS.Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat. Miner Electrolyte Metab. 1998; 24: 406–411.
39.
Harrison-BernardLM, ImigJD, CarminesPK.Renal AT1 receptor protein expression during the early stage of diabetes mellitus. Int J Exp Diabetes Res. 2002; 3: 97–108.
40.
ZimpelmannJ, KumarD, LevineDZ, . Early diabetes mellitus stimulates proximal tubule renin mrna expression in the rat. Kidney Int. 2000; 58: 2320–2330.
41.
KamiyamaM, UrusiharaM, MorikawaT, . Augmented intrarenal angiotensinogen mRNA expression parallels renal dysfunction in patients with type 2 diabetes [abstract]. Hypertension. 2010; 56: e135.
42.
WehbiGJ, ZimpelmannJ, CareyRM, . Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol. 2001; 280: F254–F265.
43.
KangJJ, TomaI, SiposA, . The collecting duct is the major source of prorenin in diabetes. Hypertension. 2008; 51: 1597–1604.
44.
NagaiY, YaoL, KoboriH, . Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol. 2005; 16: 703–711.
45.
Delete in proof.
46.
SuzakiY, OzawaY, KoboriH.Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in zucker diabetic fatty rats. Int J Biol Sci. 2007; 3: 40–46.
47.
MiyataK, OhashiN, SuzakiY, . Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2008; 35: 922–927.
48.
LorenzJN.Chymase: the other ACE?Am J Physiol Renal Physiol. 2010; 298: F35–F36.
49.
HanssonL, LindholmLH, NiskanenL, . Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999; 353: 611–616.
50.
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK prospective diabetes study group. BMJ. 1998; 317: 713–720.
51.
SchmiederRE.Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?J Hypertens Suppl. 2006; 24: S31–S35.
52.
ParvingHH, LehnertH, Brochner-MortensenJ, . Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study G. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345: 870–878.
53.
RuggenentiP, FassiA, IlievaAP, . Bergamo Nephrologic Diabetes Complications Trial I. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004; 351: 1941–1951.
54.
AgodoaLY, AppelL, BakrisGL, . African American Study of Kidney Disease and Hypertension Study G. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001; 285: 2719–2728.
55.
BrennerBM, CooperME, de ZeeuwD, . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861–869.
56.
LewisEJ, HunsickerLG, ClarkeWR, . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345: 851–860.
57.
BarnettAH, BainSC, BouterP, . Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004; 351: 1952–1961.
58.
MannJF, SchmiederRE, McQueenM, . Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372: 547–553.
59.
HallerH, ItoS, IzzoJL, . Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011; 364: 907–917.
60.
IngelfingerJR.Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes. N Engl J Med. 2011; 364: 970–971.
61.
CoreshJ, SelvinE, StevensLA, . Prevalence of chronic kidney disease in the united states. JAMA. 2007; 298: 2038–2047.
62.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med. 1993; 329: 977–986.
63.
PerkinsBA, FicocielloLH, SilvaKH, . Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003; 348: 2285–2293.
64.
WolkowPP, NiewczasMA, PerkinsB, . Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol. 2008; 19: 789–797.
65.
GouldAB, GreenD.Kinetics of the human renin and human substrate reaction. Cardiovasc Res. 1971; 5: 86–89.
66.
BrasierAR, LiJ.Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension. 1996; 27: 465–475.
67.
DingY, DavissonRL, HardyDO, . The kidney androgen-regulated protein promoter confers renal proximal tubule cell-specific and highly androgen-responsive expression on the human angiotensinogen gene in transgenic mice. J Biol Chem. 1997; 272: 28142–28148.
68.
KimuraS, MullinsJJ, BunnemannB, . High blood pressure in transgenic mice carrying the rat angiotensinogen gene. EMBO J. 1992; 11: 821–827.
69.
FukamizuA, SugimuraK, TakimotoE, . Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem. 1993; 268: 11617–11621.
70.
BohlenderJ, MenardJ, GantenD, . Angiotensinogen concentrations and renin clearance: implications for blood pressure regulation. Hypertension. 2000; 35: 780–786.
71.
SmithiesO.Theodore cooper memorial lecture. A mouse view of hypertension. Hypertension. 1997; 30: 1318–1324.
72.
MerrillDC, ThompsonMW, CarneyCL, . Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. J Clin Invest. 1996; 97: 1047–1055.
73.
KoboriH, OzawaY, SatouR, . Kidney-specific enhancement of Ang II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice. Am J Physiol Renal Physiol. 2007; 293: F938–F945.
74.
SachetelliS, LiuQ, ZhangSL, . Ras blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney Int. 2006; 69: 1016–1023.
75.
LavoieJL, Lake-BruseKD, SigmundCD.Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule. Am J Physiol Renal Physiol. 2004; 286: F965–F971.
76.
SmithiesO, KimHS.Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci U S A. 1994; 91: 3612–3615.
77.
KimHS, KregeJH, KluckmanKD, . Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A. 1995; 92: 2735–2739.
78.
InoueI, NakajimaT, WilliamsCS, . A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest. 1997; 99: 1786–1797.
79.
JeunemaitreX, SoubrierF, KotelevtsevYV, . Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992; 71: 169–180.
80.
ZhaoYY, ZhouJ, NarayananCS, . Role of C/A polymorphism at -20 on the expression of human angiotensinogen gene. Hypertension. 1999; 33: 108–115.
81.
IshigamiT, UmemuraS, TamuraK, . Essential hypertension and 5′ upstream core promoter region of human angiotensinogen gene. Hypertension. 1997; 30: 1325–1330.
82.
SchunkertH, IngelfingerJR, JacobH, . Reciprocal feedback regulation of kidney angiotensinogen and renin mRNA expressions by angiotensin II. Am J Physiol. 1992; 263: E863–E869.
83.
KoboriH, Prieto-CarrasqueroMC, OzawaY, . AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension. 2004; 43: 1126–1132.
84.
KoboriH, NishiyamaA, Harrison-BernardLM, . Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension. 2003; 41: 42–49.
KoboriH, Harrison-BernardLM, NavarLG.Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension. Hypertension. 2001; 37: 1329–1335.
87.
KoboriH, NishiyamaA.Effects of tempol on renal angiotensinogen production in Dahl salt-sensitive rats. Biochem Biophys Res Commun. 2004; 315: 746–750.
88.
KoboriH, NishiyamaA, AbeY, . Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension. 2003; 41: 592–597.
89.
KoboriH, OzawaY, SuzakiY, . Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol. 2005; 16: 2073–2080.
90.
AndersonS, JungFF, IngelfingerJR.Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol. 1993; 265: F477–F486.
91.
SinghR, SinghAK, LeeheyDJ.A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol. 2005; 288: F1183–F1190.
92.
LeeheyDJ, SinghAK, BastJP, . Glomerular renin angiotensin system in streptozotocin diabetic and zucker diabetic fatty rats. Transl Res. 2008; 151: 208–216.
93.
KoboriH, KatsuradaA, OzawaY, . Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem Biophys Res Commun. 2007; 358: 156–163.
94.
TakamatsuM, UrushiharaM, KondoS, . Glomerular angiotensinogen protein is enhanced in pediatric IgA nephropathy. Pediatr Nephrol. 2008; 23: 1257–1267.
95.
KoboriH, OzawaY, SuzakiY, . Young scholars award lecture: intratubular angiotensinogen in hypertension and kidney diseases. Am J Hypertens. 2006; 19: 541–550.
96.
KamiyamaM, ZsombokA, KoboriH.Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes. J Pharmacol Sci. 2012; 119: 314–323.
97.
ThethiT, KamiyamaM, KoboriH.The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Cur Hyperten Rep. 2012; 14: 160–169.
98.
KatsuradaA, HagiwaraY, MiyashitaK, . Novel sandwich elisa for human angiotensinogen. Am J Physiol Renal Physiol. 2007; 293: F956–F960.
99.
YamamotoT, NakagawaT, SuzukiH, . Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol. 2007; 18: 1558–1565.
100.
KoboriH, OhashiN, KatsuradaA, . Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens. 2008; 2: 349–354.
101.
NishiyamaA, KonishiY, OhashiN, . Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant. 2011; 26: 170–177.
102.
UrushiharaM, KondoS, KagamiS, . Urinary angiotensinogen accurately reflects intrarenal renin-angiotensin system activity. Am J Nephrol. 2010; 31: 318–325.
103.
KoboriH, AlperAB, ShenavaR, . Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension. 2009; 53: 344–350.
104.
KoboriH, UrushiharaM, XuJH, . Urinary angiotensinogen is correlated with blood pressure in men (Bogalusa Heart Study). J Hypertens. 2010; 28: 1422–1428.
105.
OgawaS, KoboriH, OhashiN, . Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights. 2009; 4: 97–102.
106.
SaitoT, UrushiharaM, KotaniY, . Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am J Med Sci. 2009; 338: 478–480.
